DiaMedica Therapeutics (DMAC) Q2 FY26 earnings call

DiaMedica Therapeutics made significant progress in Q2 FY26 across its DM-19 clinical programs, particularly in early onset fetal growth restriction (FGR), preeclampsia, and acute ischemic stroke. The company completed enrollment for the first FGR cohort and the late-stage preeclampsia extension, while advancing regulatory efforts for its early onset preeclampsia studies in Canada and the UK. Despite a slight delay in the Remedy 2 interim analysis to Q1 2027 due to enrollment pace, the company maintains a strong cash position through 2027 to support its pipeline milestones.